J Rheumatol 2022 May 2. Epub 2022 May 2.
S. Matsuda, MD, PhD, T. Kotani, MD, PhD, T. Suzuka, MD, PhD, T. Kiboshi, MD, Y. Wada, MD, PhD, T. Ishida, MD, PhD, H. Shiba, MD, K. Hata, MD, T. Shoda, MD, T. Takeuchi, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki; H. Kuwabara, MD, PhD, Y. Hirose, MD, PhD, Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki; Y. Fujiki, MD, PhD, Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kotani, MD, PhD, Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Daigaku-Machi 2-7, Takatsuki, Osaka 569-8686, Japan. Email: Accepted for publication April 20, 2022.
Objective: To address the pathomechanism of microscopic polyangiitis (MPA) complicated by interstitial lung disease (ILD) using serum biomarker profile and pulmonary histopathology.
Methods: Serum biomarkers from patients with MPA-ILD (n = 32), MPA without ILD (n = 17), and healthy controls (n = 10) were examined. Based on the biomarker profiles, principal component analysis (PCA) and cluster analysis were performed to classify patients with MPA-ILD into subgroups. Read More